Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News XORTX Therapeutics Inc XRTX


Primary Symbol: V.XRTX

Healthcare
XORTX Therapeutics Inc. is a Canada-based late-stage clinical pharmaceutical company. The Company develops therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications, such as autosomal dominant polycystic kidney disease (ADPKD), as well as type 2 diabetic nephropathy (T2DN) and fatty liver disease. It is working to advance... see more

Recent & Breaking News (TSXV:XRTX)

XORTX Therapeutics Receives Final Approval to List on the TSX Venture Exchange

GlobeNewswire November 2, 2021

XORTX Therapeutics (CSE:XRX) closes public offering

John Ballem  October 18, 2021

XORTX Therapeutics Announces Closing of US$12 Million Public Offering

GlobeNewswire October 15, 2021

XORTX Announces Results from Mount Sinai's COVID-19 Clinical Study

GlobeNewswire October 14, 2021

Today’s market summary: energy shortages dampen economic recovery

Trevor Abes  October 14, 2021

XORTX to Present at the LD Micro Main Event

GlobeNewswire October 14, 2021

XORTX Therapeutics (CSE:XRX) announces Nasdaq listing and $12 million public offering

Trevor Abes  October 13, 2021

XORTX Therapeutics Announces Pricing of US$12 Million Public Offering and Nasdaq Listing

GlobeNewswire October 13, 2021

CSE Bulletin: Consolidation - XORTX Therapeutics Inc. (XRX)

Newsfile September 21, 2021

XORTX Therapeutics Announces Share Consolidation

GlobeNewswire September 20, 2021

XORTX Therapeutics Reports Special Meeting Results

GlobeNewswire September 2, 2021

XORTX Therapeutics Granted European Patent

Trevor Abes  September 1, 2021

XORTX Announces Grant of European Patent

GlobeNewswire September 1, 2021

XORTX Announces New Clinical Advisory Board Member

GlobeNewswire August 31, 2021

XORTX Therapeutics Calls Special Meeting of Shareholders

GlobeNewswire August 13, 2021

XORTX Welcomes Jaqueline Le Saux to Board of Directors

GlobeNewswire June 17, 2021

XORTX (CSE:XRX) welcomes Mr. William “Bill” Farley to the Board of Directors

John Ballem  May 13, 2021

XORTX Welcomes New Member to Board of Directors

GlobeNewswire May 13, 2021

XORTX Announces Notice to Grant European Patent

GlobeNewswire April 6, 2021

XORTX to Present at "Zoom With LD MICRO"

GlobeNewswire March 16, 2021